Common use of Study Populations Clause in Contracts

Study Populations. We used the genetic data from the UK Biobank (UKB), a large-scale population-based prospective cohort study of approximately 500,000 individuals aged 40-69 years at recruitment across the United Kingdom between March 2006 and October 2010. The ethical collection of sample and full details of the genotyping and imputation are described elsewhere [14], [15]. Our study populations for each of the three disease outcomes are defined as follows: • The breast cancer eligible population was women who had not had breast cancer, carcinoma in situ or mastectomy prior to baseline. • For the hypertension eligible population, we excluded individuals with missing or implausible systolic blood pressure (SBP) measurements (< 70 or > 270 mmHg) at baseline, and those with prior Major Adverse Cardiovascular Events (▇▇▇▇). • The dementia eligible population was restricted to individuals without prior diagnosis of dementia or Alzheimer’s disease. Disease ascertainment of UKB during the following-up period utilised linkage to death registry, cancer registry, and Hospital Episode Statistics (HES). Hypertension is defined as SBP>=140 at baseline; the International Classification of Diseases (ICD) code for breast cancer and dementia can be found in Supplementary Tables 13-15.